During the past decade, South Texas Accelerated Research Therapeutics (START) conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 7 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 3 clinical trials were completed. i.e. 21.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "South Texas Accelerated Research Therapeutics (START)" #1 sponsor was "Daiichi Sankyo, Inc." with 3 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Mersana Therapeutics" with 3 trials sponsored, "Birdie Biopharmaceuticals HK Limited" with 2 trials sponsored and "Millennium Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "South Texas Accelerated Research Therapeutics (START)" #1 collaborator was "Loxo Oncology, Inc." with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Seven and Eight Biopharmaceuticals Inc" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "IQVIA Biotech" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "South Texas Accelerated Research Therapeutics (START)" are "Solid Tumors" (6 trials), "Advanced Solid Tumors" (5 trials), "Cancer" (4 trials), "Solid Tumor" (4 trials) and "Advanced Cancer" (3 trials). Many other conditions were trialed in "South Texas Accelerated Research Therapeutics (START)" in a lesser frequency.

Most popular intervention types in "South Texas Accelerated Research Therapeutics (START)" are "Drug" (40 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (3 trials), "Pembrolizumab" (3 trials), "BDB001" (2 trials), "Capecitabine" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "South Texas Accelerated Research Therapeutics (START)" are 40 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "South Texas Accelerated Research Therapeutics (START)". undefined are not yet recruiting, 11 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in South Texas Accelerated Research Therapeutics (START), undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in South Texas Accelerated Research Therapeutics (START), 39 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".